ArticleFrontiers in oncology2026
Radiomics and clinical data predict pseudoprogression after radiotherapy in high-grade glioma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: On conventional magnetic resonance imaging, pseudoprogression after radiotherapy for high-grade glioma may closely resemble true tumor progression, leading to unnecessary surgery, premature treatment escalation, or delayed appropriate therapy. We developed and internally validated an exploratory multivariable model for individualized pseudoprogression risk estimation. Methods: This single-center retrospective cohort included 222 patients with World Health Organization 2021 central nervous system grade 3 or 4 glioma who underwent surgery followed by radiotherapy at Liuzhou Workers' Hospital from January 2015 to December 2024. Pseudoprogression was adjudicated before modeling through multidisciplinary review; 13 pseudoprogression cases had histopathological confirmation, and non-histologically confirmed cases required at least 6 months of stable or improved follow-up imaging. The complete two-reader radiomics matrix was analyzed using a strict split-first workflow. Dataset partitioning preceded ICC filtering, Z-score normalization, and LASSO modeling. Results: A total of 3,404 radiomic features were analyzed. After reproducibility filtering and LASSO selection, 17 radiomic features were retained to construct the locked RadScore. In the held-out validation cohort, the integrated model combining RadScore, rCBV, ADC, NLR, MGMT promoter methylation, and TMZ treatment achieved an AUC of 0.811 (95% CI: 0.696-0.925). The clinical-imaging model without RadScore achieved a validation AUC of 0.744 (95% CI: 0.614-0.873), whereas RadScore alone achieved an AUC of 0.771 (95% CI: 0.648-0.894). Conclusion: The integrated model showed acceptable internal validation performance and provided a clinically interpretable framework for individualized PsP risk estimation by combining radiomic, perfusion-diffusion, inflammatory, molecular, and treatment-related information. External validation with standardized imaging protocols is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.